Atlas Trials

Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy

Clinical trial NCT07414758 · RECRUITING

Trial details

NCT number
NCT07414758
Sponsor
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Peripheral T Cell Lymphoma
Start date
2026-02-15
Primary completion
2028-09-30
Enrollment
68

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.